Overview

Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)

Status:
Terminated
Trial end date:
2017-11-10
Target enrollment:
Participant gender:
Summary
This study is looking at determining the maximum safe dose of CyberKnife when given with chemotherapy for unresectable adenocarcinoma of the pancreas.
Phase:
Phase 1
Details
Lead Sponsor:
The Cooper Health System
Treatments:
Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel
Pancrelipase